DOCSLIB.ORG

Marked Systemic Bleeding Tendency Caused by Disseminated

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Marked Systemic Bleeding Tendency Caused by Disseminated CASE REPORT Microscopic Polyangiitis Associated with Marked Systemic Bleeding Tendency Caused by Disseminated Intravascular Coagulation Takatoshi SAITO, Masahito TSUCHIYA, Chihiro SHIKATA, Hiroshi YAMAGUCHI, Shu-ichi MlYATA, Sei-ichiro MATSUO,Sho Ishizawa and Kunihiko YOSHIMURA Abstract Introduction A 57-year-old womanwas admitted to our hospital be- It has been well documented that anti-neutrophil cyto- cause of severe dyspnea due to pulmonaryhemorrhage plasmic antibody (ANCA)-associated vasculitis, such as and rapidly progressive renal failure. The patient was Wegener's granulomatosis and microscopic polyangiitis positive for perinuclear pattern anti-neutrophil cyto- (MPA), elicits a severe bleeding tendency as a clinical mani- plasmic antibody (p-ANCA) and was manifested with festation (1, 2). Activation of primed neutrophils induced by gastrointestinal bleeding and brain hemorrhage. Thus, ANCAand subsequent endothelial damage due to cytokine she was diagnosed as having microscopic polyangiitis release are regarded as an important initial process of (MPA). Laboratory examination demonstrated severe vasculitis, leading to hemorrhage in multiple organs and tis- thrombocytopenia, increased prothrombin time and a sues (3, 4). In addition, an increase in thrombin production high concentration of fibrin degradation products. In ad- responding to coagulation activation augments IL-8 produc- dition, the elevated plasma levels of D-dimer, thrombin- tion, which in turn activates TNF-primedneutrophils and antithrombin complex and plasmin-plasmin inhibitor further causes deterioration of systemic vasculitis (5, 6). complex led us to make a diagnosis of disseminated In contrast to MPA,disseminated intravascular coagula- intravascular coagulation (DIC). Complication of DIC tion (DIC) is also known to cause systemic bleeding ten- was considered to have caused further deterioration in dency. Similar to ANCA-associated vasculitis, impairment bleeding tendency due to MPAin the present case. The of endothelial cells causes subsequent augmentation of co- patient was treated with plasma exchange, hemodialysis, agulation and fibrinolysis through the release of proinflam- administration of corticosteroid including pulse therapy matory cytokines (7). Thus, similarity exists between the two and cyclophosphamide. Continuous infusion of gabexate diseases in pathophysiology, although it is very rare that mesilate proved effective for improvement of systemic ANCA-associated vasculitis is accompanied by DIC. bleeding tendency. However, she finally died of severe in- Here, we describe a case of MPAassociated with DIC fectious diseases. In conclusion, it is suggested that whoshowed a marked systemic bleeding tendency. Wealso ANCA-associated vasculitis could be accompanied by present evidence that gabaxate mesilate is a very effective DICand gabexate mesilate maybe a useful therapeutic therapeutic agent for DIC. agent for these disorders. (Internal Medicine 42: 850-855, 2003) Case Report Key words: anti-neutrophil cytoplasmic antibody, pulmo- A 57-year-old womanvisited our hospital complaining of nary hemorrhage, rapidly progressive pulmo- sore throat, productive cough, sputum, general fatigue and nary failure, gabexate mesilate slight fever on December ll, 2000. Her initial laboratory data showed renal insufficiency (serum creatinine and blood urea nitrogen were 1.9 mg/dl, and 24 mg/dl, respectively). Prior to onset, she had been well with no significant medical From the Division of Respiratory and Infectious Diseases, the Department of Internal Medicine, Aoto Hospital, Jikei University School of Medicine, Tokyo Received for publication June 22, 2001; Accepted for publication March 17, 2003 Reprint requests should be addressed to Dr. Takatoshi Saito, the Division of Diabetes and Endocrinology, the Department of Internal Medicine, Jikei University School of Medicine, 3-25-8 Nishishinbashi, Minato-ku, Tokyo 105-8461 850 Internal Medicine Vol. 42, No. 9 (September 2003) DIC Associated with Microscopic Polyangiitis or familial history, and she was a life-long non-smoker. antibody were negative. Hepatitis B and C serology were Despite the initial daily medication including fluticasone negative. A clotting screening test was consistent with DIC propionate (400 jug), ambroxol hydrochloride (45 mg), epra- as shown in Table 2. Urinalysis showed moderate hematuria zinone hydrochloride (60 mg) and levofloxacin (300 mg), and proteinuria. Melena was also observed. Blood gas analy- her symptomswere only slightly improved. sis under 5 //min oxygen inhalation showed severe She was admitted to our hospital due to massive hemopty- hypoxemia and hypocapnea along with metabolic acidosis sis on February 5, 2001. Her blood pressure was 122/84 (pH 7.44, PaCO2 25 torr, PaO2 50.1 torr, HCO3" 16.2 mEq/Z, mmHgrecumbent, pulse rate was 76/min regular, body base excess - 4.7 mEq/Z, SaO2 87.8%). A chest X-ray temparature was 37. 1 °C. Her conjunctiva was pale. Chest ex- showed a normal size heart, air space consolidation with air amination showed systolic heart murmurand coarse crackles bronchogram in the right lung (Fig. 1). A computerized on the right lung. Slight pitting edema and subcutaneous tomogram (CT) of the chest also demonstrated infiltrative bleeding in bilateral pretibial regions were detectable. There opacities and bilateral pleural effusion (Fig. 2). The pleural was no abnormal pigmentation, cyanosis, peripheral lymph effusion was found to be biochemically consistent with a node swelling or clubbed fingers. Neurological findings transudate, and cytological examination revealed no malig- showed no abnormalities. nant cells. Bronchoscopic examination further confirmed As shown in Table 1, hematological test revealed severe hemorrhage from the right lung (data not shown). anemia, marked thrombocytopenia and leukocytosis. Blood With the presence of rapidly progressive renal failure with chemistries showeddeteriorated renal function, electrolytes hematuria and proteinuria, pulmonary and gastrointestinal abnormalities, hypoproteinemia and elevation of C-reactive hemorrhage, subcutaneous bleeding in the bilateral pretibial protein. Immunological tests showed a high titer of P- areas, elevated CRPlevel and p-ANCAtiter in serum, as ANCA, but antinuclear antibody, cytoplasmic ANCA(C- well as chest X-ray and CTfindings, we diagnosed her as ANCA), cryoglobulin, anti-GBM antibody or anti-platelet MPAbased on diagnostic criteria made by the Vasculitis Table 1. Laboratory Data on Admission WBC (/ill) 1 3,300 Haptoglobin (mg/dl) 329 RBC (lOVfil) 144 Coombs test direct (+) Hb (g/dl) 4.7 indirect (-) Ht (%) 13.9 RF (IU/ml) 3.0> PLT (lOVjul) 3.4 ANA (+) Reticulocyte (%0) 17.3 lgG (mg/dl) 1 ,560 GOT (IU//) 17 lgA (mg/dl) 213 GPT (IU//) 7 lgM (mg/dl) 5 1 LDH (IU//) 354 PA lgG (ng/107cell) 171.9 ChE (IU//) 982 Endotoxin (pg/ml) 5> yGTP (IU//) 7 (3-D glucan (mg/dl) 8.3 ALP (IU//) 208 C3 (mg/dl) 56.0 TBi (mg/dl) 0.5 C4 (mg/dl) 14.0 IP (g/dl) 5.1 CH50 (U/ml) 19.9 Alb (g/dl) 2.0 Free T3 (pg/ml) 0.74 BUN (mg/dl) 50 Free T4 (ng/ml) 1.36 Cr (mg/dl) 4.5 TSH (jaU/ml) 1.74 Na (mEq//) 1 26 MPO-ANCA (EU) 765 K (mEq//) 5. 1 PR3-ANCA (EU) 10> Cl (mEq//) 98 Cryoglobulin (-) Ca (mg/dl) 6.5 Immuno complex (Clq: juU/ml) 5.2 P (mg/dl) 5.5 CRP (mg/dl) 9. 1 <Urinalysis> Anti legionella Ab (-) Prot (++) Anti GBMAb (-) Sugar (+) Anti platelet Ab (-) Occult (+++) LE test (-) RBC Many Anti RNP Ab (-) WBC 5-9 Anti Sm Ab (-) CCr (ml/min) 8.8 GBM: glomerular basement membrane, PA lgG: platelet-associated lgG, RNP: ribonuc- leoprotein, TSH: thyroid stimulating hormone, RF: rheumatoid factor, PR3-ANCA: proteinase 3 ANCA. Internal Medicine Vol. 42, No. 9 (September 2003) 851 Saito et al Table 2. Data for Coagulation and Fibrinolysis on Admission Values Reference intervals Prothrombin time (%) 58 70-100 Activated partial thromboplastin time (sec) 29.8 24.2-36.3 Fibrinogen (mg/dl) 303 250-400 Fibrin degradation product (jug/ml) 23.8 <10 Thrombin-antithrombin complex (ng/ml) 52. 1 <3.0 Plasmin-plasmin inhibitor complex (|ug/ml) 1.3 <0.8 Anti-thrombin III (%) 58 79-121 Plasminogen (%) 3 1 75-125 D-dimer (ng/ml) 5.3 <1.0 Figure 2. Axial computedtomographic scan of the chest show- ing severe pulmonary hemorrhage in both lungs and moderate pleural effusion. Controlled ventilation was started on the third hospital day Figure 1. Chest radiograph on admission showing bilateral via tracheal intubation. Four days later, in order to suppress progression of MPA,plasma exchange using fresh frozen massive air space consolidation due to pulmonary hemorrhage. plasma was performed three times and hemodialysis was also introduced to treat renal failure. However, FDPconcen- tration increased up to 1 12 jug/ml on 7th hospital day, indi- Study Group of the Japanese Ministry of Health and Welfare cating progression of DIC. Eventually, she developed in 1998. Furthermore, based on laboratory examination and delayed unconsciousness, and the brain CT showed small clinical features, a diagnosis of DICcould have also been high density areas indicating brain hemorrhage (Fig. 4). To made. Thrombotic microvasculopathy such as hemolytic elucidate whether anemia and thrombocytopenia were in- uremic syndrome or thrombotic thrombocytopenic purpura duced by hemophagocytic syndrome (HPS) or not (8), we were ruled out because of the absence of hemolytic anemia evaluated bone marrow. Cell counts including megakaryo- documented by several laboratory data including a low level cytes were within the normal range [cell counts 17.0x104/jul, of LDH,haptoglobin
Load more

Recommended publications
  • Syphilis Staging and Treatment Syphilis Is a Sexually Transmitted Disease (STD) Caused by the Treponema Pallidum Bacterium
    Increasing Early Syphilis Cases in Illinois – Syphilis Staging and Treatment Syphilis is a sexually transmitted disease (STD) caused by the Treponema pallidum bacterium. Syphilis can be separated into four different stages: primary, secondary, early latent, and late latent. Ocular and neurologic involvement may occur during any stage of syphilis. During the incubation period (time from exposure to clinical onset) there are no signs or symptoms of syphilis, and the individual is not infectious. Incubation can last from 10 to 90 days with an average incubation period of 21 days. During this period, the serologic testing for syphilis will be non-reactive but known contacts to early syphilis (that have been exposed within the past 90 days) should be preventatively treated. Syphilis Stages Primary 710 (CDC DX Code) Patient is most infectious Chancre (sore) must be present. It is usually marked by the appearance of a single sore, but multiple sores are common. Chancre appears at the spot where syphilis entered the body and is usually firm, round, small, and painless. The chancre lasts three to six weeks and will heal without treatment. Without medical attention the infection progresses to the secondary stage. Secondary 720 Patient is infectious This stage typically begins with a skin rash and mucous membrane lesions. The rash may manifest as rough, red, or reddish brown spots on the palms of the hands, soles of the feet, and/or torso and extremities. The rash does usually does not cause itching. Rashes associated with secondary syphilis can appear as the chancre is healing or several weeks after the chancre has healed.
    [Show full text]
  • Understanding Vasculitis Factsheet
    Vasculitis - The Facts This factsheet is intended as a simple There is no cure for PSV, but it can usually be introduction to vasculitis for those who have just controlled by use of steroids, chemotherapy and been diagnosed with vasculitis, members of their immune suppressing drugs. Long term drug therapy is family, friends, work colleagues and for others often required. If all goes well some patients go into who may want to know about the disease. “full remission” - ie they no longer need drugs. But relapse is common. What is Vasculitis Vasculitis is a rare inflammatory disease which affects People suffering from vasculitis often experience about 2-3000 new people each year in the UK. muscle weakness and chronic fatigue. Some Vasculitis means inflammation of the blood vessels. experience chronic pain due to nerve damage or Any vessels in any part of the body can be affected. severe migraines and headaches due to damaged blood vessels in the head. There are several different types of vasculitis. In the first type, the acute form, it can be caused by Others require dialysis or kidney transplants. Many infections, reaction to drugs or exposure to chemicals. have breathing problems and others are left with Often the problem is localised, such as a rash. In these permanent physical disabilities. cases the disease usually needs no treatment. Other types of vasculitis can be secondary to (or as a The most “common” types of these rare consequence of) other illnesses such as rheumatoid vasculitis diseases are: arthritis or some types of cancer. ° Granulomatosis with Polyangiitis (GPA) (previously known as Wegener’s Granulomatosis) The third group is known as Primary Systemic ° Eosinophilic Granulomatosis with Polyangiitis (EGPA) Vasculitis (PSV).
    [Show full text]
  • Comorbidities in Psoriasis: the Recognition of Psoriasis As a Systemic Disease and Current Management
    Review Derleme 71 DOI: 10.4274/turkderm.09476 Turkderm-Turk Arch Dermatol Venereology 2017;51:71-7 Comorbidities in psoriasis: The recognition of psoriasis as a systemic disease and current management Psoriazisde komorbiditeler: Psoriazisin sistemik hastalık olarak kabul edilmesi ve güncel yaklaşım Göknur Kalkan Ankara Yıldırım Beyazıt University Faculty of Medicine, Department of Dermatology, Ankara, Turkey Abstract Psoriasis, with a worldwide prevalence of 2-3%, is now assumed as a systemic chronic inflammatory disease accompanied by comorbidities while it was accepted as a disease limited only to the skin in the past. There are several classifications of the comorbidities which are more common in patients with moderate to severe psoriasis. Simply, comorbidities can be classified as classic, emerging, related to lifestyle, related to treatment. They can also be categorized as medical comorbidities, psychiatric/psychologic comorbidities, and behaviors contributing to medical and psychiatric comorbidities. In this review, providing early diagnosis and treatment of comorbidities, learning screening recommendations for early detection and long-term disease control and improvement in life quality by integrated, multidisciplinary approach were targeted. Keywords: Psoriasis, comorbidity, systemic disease Öz Tüm dünyada %2-3 oranında görülme sıklığına sahip psoriazis, geçmişte sadece deriye sınırlı kabul edilirken, günümüzde birçok komorbiditenin eşlik ettiği kronik sistemik enflamatuvar bir hastalık olarak ele alınmaktadır. Orta-şiddetli düzeyde
    [Show full text]
  • Successful Treatment with Rituximab in a Patient with TTP Secondary to Severe ANCA-Associated Vasculitis
    □ CASE REPORT □ Successful Treatment with Rituximab in a Patient with TTP Secondary to Severe ANCA-Associated Vasculitis Yukari Asamiya 1, Takahito Moriyama 1, Mari Takano 1, Chihiro Iwasaki 1, Kazuo Kimura 1, Yukako Ando 1, Akiko Aoki 1, Kan Kikuchi 2, Takashi Takei 1, Keiko Uchida 1 and Kosaku Nitta 1 Abstract We report a case of thrombotic thrombocytopenic purpura (TTP) secondary to antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis treated by rituximab. TTP secondary to ANCA-associated vasculitis is very rare and has a high mortality rate. We employed rituximab and successfully treated TTP secondary to ANCA-associated vasculitis, because standard therapies, such as steroid therapy, intravenous pulse cyclophos- phamide, and repeated plasma exchange (PE), did not suppress her disease activity. This is the first report to suggest that rituximab can achieve complete remission of TTP secondary to ANCA-associated vasculitis. Key words: ANCA-associated vasculitis, TTP, rituximab, renal failure, intrapulmonary hemorrhage, hemo- dialysis (Inter Med 49: 1587-1591, 2010) (DOI: 10.2169/internalmedicine.49.3135) pies such as steroids and therapeutic PE (4-6). However, ri- Introduction tuximab was employed mainly against idiopathic TTP, and there were few reports discussing treatment of secondary Antineutrophil cytoplasmic antibody (ANCA)-associated TTP; in particular, TTP with ANCA-associated vasculitis vasculitis is recognized as a multisystem autoimmune dis- was rare. Here, we report a patient with TTP secondary to ease characterized by ANCA production and small vessel in- myeloperoxidase-antineutrophil cytoplasmic antibody (MPO- flammation (1). It’s typical clinical manifestations are rap- ANCA) associated vasculitis who was treated using rituxi- idly progressive glomerulonephritis and the occasional de- mab combined with steroid pulse, IVCY and repeated PE.
    [Show full text]
  • Syphilis Imitating Urticarial Vasculitis
    PRACTICE | CLINICAL IMAGES Syphilis imitating urticarial vasculitis Hideaki Miyachi MD PhD, Toshibumi Taniguchi MD PhD, Hiroyuki Matsue MD PhD n Cite as: CMAJ 2019 December 16;191:E1384. doi: 10.1503/cmaj.190469 See related article at www.cmaj.ca/lookup/doi/10.1503/cmaj.191075 27-year-old previously healthy woman presented with a 2-month history of recurrent raised pruritic erythematous plaques resembling urticaria that persisted for more than 24A hours (Figure 1). She was otherwise asymptomatic, with no his- tory of fever or mucosal lesions. Previous treatments with orally administered H1 antihistamines and corticosteroids were ineffec- tive. Skin biopsy showed perivascular inflammatory cell infiltration with some nuclear debris and swelling of endothelial cells involving postcapillary venules, whereas plasma cell infiltration was nearly absent (Appendix 1, Supplementary Figure 1, available at www. cmaj.ca/lookup/suppl/doi:10.1503/cmaj.190469/-/DC1). Direct immunofluorescence showed the deposition of complement and fibrinogen around blood vessels and in the dermal–epidermal junc- tion, consistent with urticarial vasculitis. However, complement Figure 1: Raised pruritic erythematous plaques resembling urticaria in a levels were unremarkable, and the C1q solid-phase test for immune 27-year-old woman with secondary syphilis. complexes was negative, excluding hypocomplementemic urticar- ial vasculitis. Autoantibodies associated with connective tissue dis- References eases were not detected. 1. Tanizaki R, Nichijima T, Aoki T, et al. High-dose oral amoxicillin plus probenecid Serologic tests for HIV, hepatitis B virus and hepatitis C virus is highly effective for syphillis in patients with HIV infection. Clin Infect Dis 2015; 61:177-83. were negative; however, the rapid plasma reagin test was positive (titer, 1:128), and the Treponema pallidum hemagglutination assay 2.
    [Show full text]
  • Cerebral Vasculitis Associated with Shingles J D M Edgar, J J Crosbie, S a Hawkins
    The Ulster Medical Joumal, Volume 59, No. 1, pp. 77- 81, April 1990. Case report Cerebral vasculitis associated with shingles J D M Edgar, J J Crosbie, S A Hawkins Accepted 9 August 1989. Shingles is a common manifestation of infection with herpes zoster virus (more correctly varicella-zoster virus) in middle-aged or elderly people. We describe three patients who developed brain stem encephalitis and cerebral vasculitis due to infection with this agent during a 12-month period. CASE 1 A 77-year-old lady initially presented to her family doctor in January 1987. She complained of a painful left ear with associated hearing loss and dizziness. There were vesicles on the left pinna, and she had a left lower motor neurone facial palsy. She was treated for five days with oral acyclovir and topical idoxuridine, but her symptoms did not resolve. Two weeks after the onset she became ataxic, with double vision and nausea. She was admitted to an ear, nose and throat ward, and a neurological opinion was sought. She was fully alert and orientated. There were vesicles on the left pinna. She had gaze -evoked nystagmus on horizontal and vertical gaze, maximum on left lateral gaze. There was a complete left lower motor neurone facial palsy. There was a right carotid artery bruit. There were no other cranial nerve lesions. Power and sensation were fully intact, tendon reflexes were symmetrical but the left plantar response was extensor. She had marked truncal ataxia and left - sided inco - ordination. Computerised tomography scan of the head showed evidence of cerebral atrophy but no focal lesion.
    [Show full text]
  • Proliferative Lupus Nephritis and Leukocytoclastic Vasculitis During Treatment with Etanercept ADAM MOR, CLIFTON O
    Case Report Proliferative Lupus Nephritis and Leukocytoclastic Vasculitis During Treatment with Etanercept ADAM MOR, CLIFTON O. BINGHAM III, LAURA BARISONI, EILEEN LYDON, and H. MICHAEL BELMONT ABSTRACT. Tumor necrosis factor-α (TNF-α) is a proinflammatory cytokine. Agents that neutralize TNF-α are effective in the treatment of disorders such as rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), spondyloarthropathies, and inflammatory bowel disease. TNF-α antagonist therapy has been associated with the development of antinuclear antibodies (ANA) and double-stranded DNA (dsDNA) antibodies, as well as the infrequent development of systemic lupus erythematosus (SLE)- like disease. We describe the first case of biopsy-confirmed proliferative lupus nephritis and leuko- cytoclastic vasculitis in a patient treated with etanercept for JRA. (J Rheumatol 2005; 32:740–3) Key Indexing Terms: TUMOR NECROSIS FACTOR SYSTEMIC LUPUS ERYTHEMATOSUS NEPHRITIS VASCULITIS ETANERCEPT Tumor necrosis factor-α (TNF-α) is a proinflammatory CASE REPORT cytokine involved in the pathogenesis of several inflamma- A 22-year-old woman presented with a purpuric rash and lower extremity tory and autoimmune diseases1. Agents that neutralize TNF edema. At 14 years of age she was diagnosed with polyarticular JRA after are effective in the treatment of disorders such as rheuma- presenting with symmetric arthritis of hands, shoulders, ankles, and knees. C-reactive protein (CRP) and erythrocyte sedimentation rate were elevated, toid arthritis, juvenile rheumatoid arthritis (JRA), spondy- while both ANA and rheumatoid factor (RF) were negative. During her dis- loarthropathies, and inflammatory bowel disease. One TNF ease course she did not experience any extraarticular manifestations. She antagonist is etanercept, a soluble type II TNF receptor was treated with multiple disease modifying antirheumatic drugs [e.g, (p75) fused to the Fc portion of human immunoglobulin (Ig) plaquenil, sulfasalazine, and methotrexate (MTX)] without achieving com- G1.
    [Show full text]
  • Neurologic Complications of the Reactivation of Varicella–Zoster Virus
    MEDICAL PROGRESS Review Article Medical Progress the infected person; however, the biologic mechanisms that underlie the transition from latency to active viral replication are unknown. Many laboratories have made NEUROLOGIC COMPLICATIONS serious efforts to determine the physical state of the virus during latency, because understanding this state OF THE REACTIVATION is essential to predicting or preventing the neurologic OF VARICELLA–ZOSTER VIRUS complications produced by reactivation of the virus. DONALD H. GILDEN, M.D., DNA of Varicella–Zoster Virus in Human Ganglia B.K. KLEINSCHMIDT-DEMASTERS, M.D., After it has produced chickenpox, varicella–zoster JAMES J. LAGUARDIA, M.D., RAVI MAHALINGAM, PH.D., virus becomes latent in ganglia along the entire neu- AND RANDALL J. COHRS, PH.D. raxis. Unlike herpes simplex virus, however, varicella– zoster virus cannot be cultured from human gan- glia.3 Although clinicians had long suspected that the ARICELLA–ZOSTER virus is an exclusive- ganglia were the site of latency, verification came only ly human herpesvirus that causes chickenpox after latent varicella–zoster virus was detected in hu- V (varicella), becomes latent in cranial-nerve and man trigeminal and thoracic ganglia by means of dorsal-root ganglia, and frequently reactivates decades Southern blot analysis and in situ hybridization.4-6 A later to produce shingles (zoster) and postherpetic PCR analysis that revealed varicella–zoster viral DNA neuralgia. In immunocompetent elderly persons or in trigeminal ganglia from 13 of 15 subjects and
    [Show full text]
  • Versus Arthritis Vasculitis Information Booklet
    Condition Vasculitis Vasculitis This booklet provides information and answers to your questions about this condition. Arthritis Research UK booklets are produced and printed entirely from charitable donations. What is vasculitis? Vasculitis means inflammation of the blood vessels. There are several different types of the condition, many with unknown causes, but treatments can be very effective. In this booklet we’ll briefly explain the main types of vasculitis, how they’re diagnosed and treated, what you can do to help yourself and where to get more information. At the back of this booklet you’ll find a brief glossary of medical words – we’ve underlined these when they’re first used. www.arthritisresearchuk.org Page 2 of 32 Vasculitis information booklet Arthritis Research UK What’s inside? 2 Vasculitis at a glance 5 Who diagnoses and treats 15 What is the outlook? vasculitis? 15 How is vasculitis diagnosed? 6 What is vasculitis? – What tests are there? 8 What are the symptoms 17 What treatments are there for vasculitis? of vasculitis? – Drugs 9 What types of vasculitis 20 Self-help and daily living are there? – Exercise – Takayasu arteritis (TA) – Diet and nutrition – Giant cell arteritis (temporal arteritis) – Stop smoking – Polyarteritis nodosa (PAN) – Keep warm – Kawasaki disease 22 Research and new – Granulomatosis with polyangiitis developments (Wegener’s granulomatosis) 23 Glossary – Behçet’s syndrome – Eosinophilic granulomatosis 26 Where can I find out more? with polyangiitis (Churg–Strauss 28 We’re here to help syndrome) – Microscopic polyangiitis – Cryoglobulin-associated vasculitis – Immunoglobulin A vasculitis (Henoch–Schönlein purpura) 14 Who gets vasculitis? 15 What causes vasculitis? Page 3 of 32 Vasculitis information booklet At a glance Vasculitis There are several different types of vasculitis but all are treatable.
    [Show full text]
  • CNS Vasculitis As a Manifestation of Systemic Sclerosis Corey E
    CNS Vasculitis as a Manifestation of Systemic Sclerosis Corey E. Goldsmith, MD and Joseph S. Kass, MD Department of Neurology, Ben Taub General Hospital, Baylor College of Medicine, Houston, TX Harris County Hospital District Neither author has anything to disclose INTRODUCTION CASE REPORT, cont DISCUSSION Systemic sclerosis (or scleroderma) is a connective tissue Figure 1. CT and MRI Brain Imaging Systemic sclerosis is a connective tissue disease of disease manifested by rapidly progressive fibrosis of the skin, unknown etiology which causes rapidly progressive fibrosis of lungs, and other internal organs usually felt to have rare the skin, lungs, and other internal organs. Currently, cranial secondary central nervous system (CNS) manifestations. We and autonomic neuropathies are widely recognized present a patient with extensive CNS involvement of systemic neurological associations with systemic sclerosis, but central sclerosis consistent with a diffuse CNS vasculitis. Recent nervous system manifestations are much rarer. This case evidence supports a more direct role of the central nervous A B C shows the most extensive involvement of the central nervous system in systemic sclerosis. system in systemic sclerosis of which we are aware with CASE REPORT serologic and imaging evidence of vasculitis. Previous literature has hypothesized that the CNS A 24 year-old right-handed woman with a two year history involvement in systemic sclerosis is due to a secondary of advanced systemic sclerosis treated with prednisone 10mg DE vasculopathy. However, there is argument for a more primary daily presented with a week-long history of progressive CT head without contrast (A) shows multiple calcifications. MRI FLAIR (B) involvement of the central nervous system.
    [Show full text]
  • Vasculitis and Systemic Lupus Erythematous (SLE) Elisabetta Cortis*, Maria Greca Magnolia from 71St Congress of the Italian Society of Pediatrics
    Cortis and Magnolia Italian Journal of Pediatrics 2015, 41(Suppl 2):A20 http://www.ijponline.net/content/41/S2/A20 MEETINGABSTRACT Open Access Vasculitis and Systemic Lupus Erythematous (SLE) Elisabetta Cortis*, Maria Greca Magnolia From 71st Congress of the Italian Society of Pediatrics. Joint National Meeting SIP, SIMGePeD, Study Group on Pediatric Ultrasound, SUP Study Group on Hypertension Rome, Italy. 4-6 June 2015 Vasculitis are a heterogeneous group of disorders char- Table 1. Vasculitis: classification (Adapted from EULAR/ acterized by inflammation of the blood vessels of differ- PReS endorsed criteria for the classification of childhood ent caliber and sometimes fibrinoid necrosis with vessel vasculitis) 2006; 65:936-41 wall destruction [1]. Vasculitis in large calibre vessels prevalence Vasculitis are divided into cutaneous and systemic • Takayasu arteritis forms, primary and secondary to hypertension, immuno- Vasculitis in medium caliber vessels prevalence • Nodose Polyarteritis suppression therapy, metabolic complications. The clas- • Cutaneous polyarteritis sification is based on the affected vessel size (Table 1). • Kawasaki desease They may have neurological manifestations at the onset Vasculitis in small calibre vessels A. Granulomatous and during the desease development. These are more • Wegener Granulomatosis common in systemic forms such as SLE and Nodose • Churg-Strauss syndrome Polyarteritis (PAN). B. Non granulomatous • Microscopic polyangiitis The Schonlein-Henoch purpura and Kawasaki disease, • Schönlein-Henoch syndrome the most frequent vasculitisin childhood, rarely can have • LVC isolated • neurological disorders. There are forms of mild to mod- Urticarial vasculitis ipocomplementemica Other forms erate intensity like headache, irritability, mood disorders • Behcet desease and behavioral and forms of severe as seizures and sen- • Vasculitis secondary to infection (including nodose sory disturbance up to coma.
    [Show full text]
  • Vasculitis Factsheet Dr Laurence Knott Dr David Kluth
    Author Peer Reviewer Vasculitis Factsheet Dr Laurence Knott Dr David Kluth This is a leaflet for people who want general information about vasculitis. Vasculitis is a medical term meaning inflammation of blood vessels. It can be primary (occurring on its own) or secondary (occurring as part of another condition). Some people with vasculitis test positive for antibodies to constituents of certain white blood cells (anti-neutrophil cytoplasmic antibodies or ANCA) and are said to have ANCA vasculitis. Who gets vasculitis? Vasculitis is an uncommon illness. About 20 in every 100,000 people get ANCA vasculitis every year in the UK. Vasculitis can affect all age groups. Some are mostly diseases of childhood (e.g. Kawasaki), whilst others persist throughout adult life (ANCA systemic vasculitis). Some principally affect the elderly (e.g. giant cell arteritis). What causes vasculitis? In most cases the cause is not known. Many experts think that the illness is the result of infection in people who were born with a certain genetic predisposition. Vasculitis can also be caused by illnesses which trigger inflammation in the body such as rheumatoid arthritis and inflammatory diseases of the bowel. Medicines associated with vasculitis include certain types of antibiotics (e.g. quinolones, sulphonamides,beta-lactams), a nti-inflammatories, the contraceptive pill, some types of fluid tablets (thiazides) and flu vaccines. Rare types of cancer (paraproteinaemia, lymphoproliferative disorder) can occasionally cause vasculitis. Are there different types of vasculitis? There are many different types of vasculitis and various ways of classifying them. Vasculitis occurring in one part of the body is known as localised vasculitis.
    [Show full text]